Ophthalmic drugs contract manufacturing market is estimated to be worth USD 1.7 billion in 2030, predicts {Roots Analysis}

 

Outsourcing has become a popular trend among ophthalmic drug developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.”

 

The report features an extensive study of the contract services market for ophthalmic products and solutions. It features in-depth analyses, highlighting the capabilities of a diverse set of CMOs and CDMOs. Amongst other elements, the report includes:

§  A detailed review of the ophthalmic drugs contract manufacturing market landscape, featuring a list of over 240 CMOs and analysis based on a number of relevant parameters.

§  A competitiveness analysis of prominent contract manufacturers, featuring insightful pictorial summaries and representations.

§  Elaborate profiles of key players that offer a diverse range of capabilities for the contract development, manufacturing and packaging of ophthalmic drug products.

§  A detailed clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products.

§  An estimate of the overall, annual capacity for manufacturing ophthalmic APIs and drug FDFs based on data reported by industry stakeholders in the public domain.

§  An informed estimate of the annual clinical and commercial demand for ophthalmic APIs and drug FDFs.

§  A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, including a Harvey ball analysis highlighting the relative effect of each SWOT parameter on the overall industry.

§  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract manufacturing services to ophthalmic drug developers.

§  A discussion on the emerging trends and potential market drivers, which are likely to impact the evolution of the market in the coming years.

§  A detailed list of over 55 ophthalmic medical device contract manufacturers, along with information on a number of relevant parameters.

 

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Type of product

§  Ophthalmic API

§  Ophthalmic drug FDF

 

§  Type of FDF manufactured

§  Solid

§  Semi-solid

§  Liquid / suspension

 

§  Type of primary packaging

§  Ampoule / vial 

§  Glass / plastic bottle

§  Ointment tube

§  Blister packing

§  Other forms

 

§  Scale of manufacturing

§  Clinical

§  Commercial

 

§  Company size

§  Small

§  Mid-sized

§  Large

§  Very large

 

§  Target disease indication

§  Age-related macular degeneration

§  Dry eye

§  Glaucoma

§  Other disease segments

 

§  Key geographical regions

§  North America (US, Canada and Mexico)

§  Europe (UK, Germany, France, Spain, Italy and rest of Europe)

§  Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)

§  Rest of the world

 

Key companies covered in the report

§  Akorn

§  Akums

§  Bal Pharma

§  Catalent

§  Cayman Chemical

§  Entod Pharmaceuticals

§  Farmigea

§  Glenmark Pharmaceuticals

§  Indiana Ophthalmics

§  Lomapharm

§  Medichem

§  Pillar5 Pharma

§  Recipharm

§  Salvat

§  Sterling Pharmaceutical Services

§  Sunways India

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

 

Other Recent Offerings

  1. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
  2. Pharmaceutical Continuous Manufacturing Market, 2020-2030
  3. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com

 

Comments

Post a Comment

Popular posts from this blog

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

    Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals   Roots Analysis is pleased to announce the publication of its recent study, titled “ Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 ” report to its list of offerings.   The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the r...
Read more

PRE-INSTALLED SINGLE-USE SENSORS FOR BIOPROCESSING-CASE STUDY

    During our research, we identified 31 pre-installed single-use sensors developed by various companies for bioprocessing. The current market landscape is predominantly characterized by the presence of large (38%) and small (37%) players. Notable examples of large players in this domain include ( in alphabetical order ) Cytiva Life Sciences (US), Hamilton (US) and Pall (US).   To Request Sample Pages -: https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html       Majority of the pre-installed single-use sensor systems are designed for both, research and biomanufacturing purposes. This is followed by those designed for only research purposes. Notable examples of products which are developed for both research and biomanufacturing applications, include ( arranged alphabetically ) ÄKTA ready XL sensor technology (Cytiva Life Sciences), Allegro™ MVP Single-Use System (Pall Corporation) and FUTURA pico (Aber Instruments)...
Read more